JonathanHarrySchatzMD

PubMed

• 6 citations
  Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
  Asaad Trabolsi, Artavazd Arumov, Jonathan H Schatz
  Blood Cancer Journal. 2024-02-08
• 422 citations
  Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation.
  Roger Sciammas, Arthur L. Shaffer, Jonathan H. Schatz, Hong Zhao, Louis M. Staudt
  Immunity. 2006-08-01
• 437 citations
  RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
  Andrew Wolfe, Kamini Singh, Yi Zhong, Philipp Drewe, Vinagolu K. Rajasekhar
  Nature. 2014-09-04

Journal Articles

• Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells  
  Amin AD, Rajan SS, Groysman MJ, Pongtornpipat P, Schatz JH, Biomarkers in Cancer, 1/15/2015
• Kinase overexpressing cancers responsive to drug withdrawal  
  Amin AD, Rajan SS, Schatz JH, Aging, 1/1/2015
• Evidence suggesting that discontinuous dosing of ALK kinase inhibitors may prolong control of ALK+ tumors  
  Amin AD, Rajan SS, Lang WS, Pongtornpipat P, Groysman MJ, Tapia EO, Tula-Sanchez AA, Peters TL, Cuyugan L, Adkins J, Rimsza LM, Lussier YA, Puvvada SD, Schatz JH, Cancer Research, 1/1/2015
• Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibitor ABT-199 Combined with Pharmacologic Loss of MCL1  
  Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, Rimsza LM, Puvvada SD, Schatz JH, Leukemia, 1/1/2015
• A Rare Presentation of in-situ Mantle Cell Lymphoma and Follicular Lymphoma: A Case Report & Review of the Literature  
  Taverna J, Nair A, Yun S, Paulson S, Schatz JH, Persky DO, Fuchs D, Puvvada SD, Case Rep Hematol, 1/1/2014
• Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy  
  Oricchio E, Ciriello G, Jiang M, Boice MH, Schatz JH, Heguy A, Viale A, de Stanchina E, Teruya-Feldstein J, Bouska A, McKeithan T, Sander C, Tam W, Seshan V, Chan J, C..., Journal of Experimental Medicine, 1/1/2014
• A Targeted Mutational Landscape of Angioimmunoblastic T-cell Lymphoma  
  Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Steven..., Blood, 1/1/2014
• Progress Against Follicular Lymphoma  
  Schatz JH, Oricchio E, Puvvada SD, Wendel HG, Current Opinion in Hematology, 1/1/2013
• Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin Lymphoma: Results, Biology, and Development Strategies  
  Schatz JH, Curr Oncol Rep, 1/1/2011
• Join now to see all

Abstracts/Posters

• Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics
  Jonathan H. Schatz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint R...
  Jonathan H. Schatz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
  Jonathan H. Schatz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Exploring the Mechanisms of Toxic ALK Overdose in Anaplastic Large-Cell Lymphoma.
  Soumya S. Rajan, Amit Dipak Amin, Lingxiao Li, Praechompoo Pongtornpipat, Emmanuel Petricoin, Jonathan H. Schatz, T-Cell Lymphoma Forum, 1/1/2016
• Over-expression of NPM-ALK drives resistance to TKIs in ALK+ ALCL but is toxic upon drug withdrawal, permitting prolonged tumour control through discontinuous dosing.
  Soumya Sundara Rajan, Amit Dipak Amin, Matthew Groysman, Praechompoo Pongtornpipat, Jonathan Schatz, American Association of Cancer Research Annual Meeting, 1/1/2015
• Novel Resistance Mutations to ALK Tyrosine Kinase Inhibition Arising During Cell-Culture Drug Selections in T-Cell Lymphoma.
  Matthew Groysman, Amit Dipak Amin, Edgar Tapia, Soumya Rajan, Jonathan Schatz, American Society for Biochemistry and Molecular Biology 2015 Annual Meeting, 1/1/2015
• Preclinical models of resistance to ALK-kinase inhibition in anaplastic large-cell lymphoma highlight a potential for intermittent dosing exploiting oncogene overdose.
  Amit Dipak Amin, Soumya Rajan, Matthew Groysman, Tara Peters, Prae Pongtornpipat, Soham Puvvada and Jonathan Schatz, American Society of Hematology Meeting on Lymphoma Biology, 1/1/2014
• Activated B-Cell DLBCL with Downstream Activation of Survival Signaling Requires PIM Kinase Activity to Maintain Oncoprotein Translation.
  Tara L. Peters, Ana A. Tula-Sanchez, Nicolette Brown, Prae Pongtornpipat, Mengdie Wang, Soham D. Puvvada, Jonathan H. Schatz, American Society of Hematology Annual Meeting, 1/1/2014
• Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1.
  Lingxiao Li, Praechompoo Pongtornpipat, Timothy Tiutan, Samantha L. Kendrick, Soyoung Park, Daniel O Persky, Lisa M. Rimsza, Soham D. Puvvada, and Jonathan H. Schatz, American Society of Hematology Annual Meeting, 1/1/2014
• Targeting MCL1 and BCL2 Simultaneously Shows High Potency Against DLBCL.
  Lingxiao Li, Ph.D., Praechampoo Pongtornpipat, B.S., Soyoung Park, M.D., Jonathan H. Schatz, M.D., American Society of Clinical Oncology 2014 Annual Meeting, 1/1/2014
• Pan-PIM kinase inhibition with LGH447 shows efficacy against ABC-DLBCL but increases PIM levels through reduced protein turnover.
  Tula-Sanchez Ana, Peters Tara, Brown Nicolette, Pongtornpipat Prae, Wang Mengdie, Soham D. Puvvada, Schatz Jonathan, ASH Meeting on Lymphoma Biology, 1/1/2014
• Next-Generation Sequencing Suggests Complex, Heterogeneous Pathogenesis in Peripheral T-Cell Lymphoma Unspecified.
  Jonathan H. Schatz, Steven M. Horwitz, Matthew A. Lunning, Igor Dolgalev, Kety Huberman, Adriana Heguy, Agnes Viale, Mono Pirun, Nicholas D. Socci, Julie Teruya-Feldst..., American Society of Hematology 2013 Annual Meeting, 1/1/2013
• Targeting MYC Expression with CDK Inhibitors Shows Potency in Preclinical Models of High-Risk Diffuse Large B-Cell Lymphoma.
  Lingxiao Li, Prae Pongtornpipat, Soham D. Puvvada, and Jonathan H. Schatz, American Society of Hematology 2013 Annual Meeting, 1/1/2013
• Induced Dependence on the ALK Kinase Inhibitor Crizotinib in Formerly Sensitive Anaplastic Large Cell Lymphoma Cells.
  Amit Dipak Amin, Prae Pongtornpipat and Jonathan Schatz, American Society of Hematology 2013 Annual Meeting, 1/1/2013
• MicroRNAs Mediate Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive B-ALL by Down-Regulating Key Tumor Suppressors.
  Jonathan H. Schatz, Michael Boice, Konstantinos J. Mavrakis, Andrew L. Wolfe, and Hans-Guido Wendel, American Society of Hematology Annual Meeting, 1/1/2011
• Therapeutic Inhibition of Cap-Dependent Translation Coordinately Blocks Redundant AKT and PIM Kinase Signals in Lymphoma.
  Jonathan H. Schatz, Elisa Oricchio, Man Jiang, Irina Linkov, Jocelyn Maragulia, Weiji Shi, Zhigang Zhang, Julie Teruya-Feldstein, Andrew Zelenetz, and Hans-Guido Wendel, Geoffrey Beene Cancer Research Center Symposium, 1/1/2011
• Targeting Cap-Dependent Translation to Bypass Pro-Survival Signaling by AKT and the Pim Family Kinases in Non-Hodgkin Lymphoma.
  Jonathan H. Schatz, Elisa Oricchio, Man Jiang, Irina Linkov, Jocelyn Maragulia, Weiji Shi, Zhigang Zhang, Julie Teruya-Feldstein, Andrew Zelenetz, and Hans-Guido Wendel, International Congress on Malignant Lymphoma, Lugano, Switzerland, 1/1/2011
• Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker In Lymphoma.
  Jonathan H. Schatz, Julie Teruya-Feldstein, Man Jiang, Andrew D Zelenetz, and Hans-Guido Wendel, American Society of Hematology Annual Meeting, 1/1/2010
• Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker in Lymphoma.
  Jonathan H. Schatz, Julie Teruya-Feldstein, Man Jiang, Andrew D. Zelenetz, and Hans-Guido Wendel, Mechanisms and Models of Cancer 2010, Cold Spring Harbor, 1/1/2010
• Oncogenic Pim Kinase Activity Provides Resistance to Mtor Inhibition in Vitro and In Vivo.
  Jonathan Schatz and Hans-Guido Wendel, American Society of Hematology Annual Meeting, 1/1/2009
• IRF-4 Functions as a Myeloid Tumor Suppressor.
  Jonathan H. Schatz and Harinder Singh, 2006 ACP Annual Meeting, 1/1/2006
• IRF-4 Functions as a Myeloid Tumor Suppressor.
  Jaime Acquaviva Jonathan Schatz Harinder Singh Ruibao Ren, American Society of Hematology Annual Meeting, 1/1/2006
• IRF-4 Functions as a Myeloid Tumor Suppressor.
  Jonathan H. Schatz and Harinder Singh, American College of Physicians, Northern Illinois Chapter Scientific Meeting, 1/1/2005
• Loss of IRF-4 Exacerbates CML-like Phenotype of IRF-8 Knockout Mice.
  Jonathan Schatz, Ruibao Ren, and Harinder Singh, American Society of Hematology Annual Meeting, 1/1/2004
• The Transcription Factors IRF-4 and IRF-8: New Insights on Myeloid Development and the Pathogenesis of Chronic Myeloid Leukemia.
  Jonathan Schatz and Harinder Singh, Senior Scientific Forum, University of Chicago Pritzker School of Medicine, 1/1/2004
• Join now to see all

Lectures

• Discovery and Early Characterization of a New Inhibitor of Cap-Dependent Translation for Cancer Therapy. 
  University of Miami - 1/1/2016
• The China Lymphoma Project: A Medical Perspective. 
  1/1/2016
• Studies of Preclinical Therapeutics and Resistance in Lymphoma Model Systems. 
  University of Arizona - 1/1/2015
• Is Oncogene Overdose a New Achilles Heel for Kinase-Addicted Cancers? 
  University of Arizona - 1/1/2015
• Oncogene Overdose: Exploring A New Paradigm in Cancer Therapy. 
  University of Miami - 1/1/2015
• Exploring new treatments for lymphoma in the lab. 
  1/1/2015
• Oncogene Overdose in Cancer Therapy Resistance: Can We Use it to Help Patients? 
  1/1/2015
• Mining Resistance Mechanisms for New Therapeutic Strategies in Lymphoma. 
  University of Arizona - 1/1/2014
• "Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1." 
  1/1/2014
• New Drug Strategies for Lymphoma: Looking for Simple Targets in Complex Cancers. 
  University of Arizona - 1/1/2013
• "Next-Generation Sequencing Suggests Therapeutic Targets in Peripheral T-Cell Lymphoma" 
  Lugano, Switzerland - 1/1/2013
• "Next-Generation Sequencing Suggests Complex, Heterogeneous Pathogenesis in Peripheral T-Cell Lymphoma Unspecified" 
  1/1/2013
• New Approaches to Overcome Treatment Resistance in Lymphoma. 
  University of Arizona - 1/1/2012
• "Targeting Cap-Dependent Translation to Bypass AKT and the PIM Family Kinases in Non-Hodgkin Lymphoma" 
  Lugano, Switzerland - 1/1/2011
• Targeting Cap-Dependent Translation Bypasses Parallel Survival Signals in Non-Hodgkin Lymphoma. 
  Memorial Sloan-Kettering Cancer Center - 1/1/2011
• "Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker in Lymphoma" 
  1/1/2010
• Emerging Targets: The PIM Family Kinases in Lymphomagenesis and Resistance to Therapy. 
  Memorial Sloan-Kettering Cancer Center - 1/1/2009
• Join now to see all